What are the lesser-known symptoms of hematologic malignancies such as leukemia, lymphoma, and multiple myeloma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lesser-Known Symptoms of Blood Malignancies

Beyond the classic fever, night sweats, and lymphadenopathy, hematologic malignancies frequently present with cutaneous manifestations, neurological symptoms, ocular involvement, and can masquerade as rheumatologic diseases—all of which are commonly overlooked or misdiagnosed in clinical practice.

Cutaneous and Mucocutaneous Manifestations

Skin involvement occurs in up to 87.57% of patients with leukemia and lymphoma, yet is frequently misinterpreted 1. These manifestations fall into two categories:

Specific Cutaneous Findings

  • Leukemia cutis: Direct infiltration of malignant cells into the skin (0.56% of cases) 1
  • Gingival hyperplasia: Particularly in acute myeloid leukemia (3.39% of cases) 1
  • Leukemic vasculitis: (1.13% of cases) 1
  • Skin lesions in BPDCN: Can involve lymph nodes, spleen, and extramedullary organs, with approximately 10% presenting with isolated cutaneous lesions before systemic disease becomes apparent 2

Non-Specific Cutaneous Findings

  • Thrombocytopenic purpura: Significantly associated with AML (p<0.001) 1
  • Xerosis (dry skin): More common in AML (p=0.023) 1
  • Bacterial skin infections: Higher frequency in AML (p=0.028) 1
  • Hyperpigmentation: Particularly with immunomodulatory drugs (IMiDs) in Black/African American patients 3

Clinical Pearl: AML shows the highest frequency (96.88%) of mucocutaneous involvement among all hematologic malignancies 1. When patients present with unexplained skin lesions, especially with concurrent cytopenias, biopsy by experienced hematopathologists is essential 2.

Neurological Manifestations

CNS involvement is substantially underrecognized:

  • CNS disease at diagnosis: Approximately 10% of patients with neurologic symptoms have confirmed CNS involvement 2
  • Overall CNS involvement rates: Range from 9% to 26% at diagnosis and relapse 2
  • Presentation: Can occur without skin manifestations in acute leukemias 2

Critical Action: For BPDCN specifically, lumbar puncture is highly recommended at initial diagnosis even in asymptomatic patients, with subsequent intrathecal prophylaxis strongly encouraged 2.

Ocular Manifestations

Eye involvement represents a frequently missed presentation 4:

  • Retinal hemorrhage
  • Vitreoretinal lymphoma
  • Choroidal infiltration
  • Orbital masses

Diagnostic Challenge: These findings may mimic other ocular diseases and lead to delayed diagnosis. In some cases, ocular manifestations represent the initial presentation or indicate disease recurrence 4. Comprehensive ophthalmic examination should be considered in patients with unexplained visual symptoms and known or suspected hematologic malignancy.

Rheumatologic Mimicry

Hematologic malignancies can present as seemingly primary rheumatologic diseases 5:

Common Rheumatologic Presentations

  • Polyarthritis
  • Vasculitis
  • Raynaud phenomenon
  • Systemic symptoms: Weight loss, fatigue, night sweats

Diagnostic Pitfall: Misleading autoimmune serologies and transient responses to immunosuppressive therapy frequently delay diagnosis 5. The underlying malignancies ultimately identified include:

  • Angioimmunoblastic T-cell lymphoma (AITL)
  • Extranodal marginal zone lymphoma
  • Myelodysplastic syndrome (MDS)
  • Multiple myeloma 5

Red Flags: Consider hematologic malignancy when rheumatologic symptoms are atypical, refractory to standard therapy, or accompanied by unexplained cytopenias or constitutional symptoms 5.

Hepatic Involvement

Solitary liver lesions without cirrhosis or elevated tumor markers (AFP, CEA, CA19-9) can represent 6:

  • Primary hepatic lymphoma (PHL)
  • Hepatic plasmacytoma (rare)
  • Multiple myeloma liver involvement

Imaging Characteristics: Hypodense lesions on CT or hypointense on T1-weighted MRI with variable enhancement 6. Liver function tests are frequently normal, making this particularly deceptive 6.

Symptom Burden Patterns by Disease Type

Recent data reveals disease-specific symptom profiles 7:

Multiple Myeloma

  • Fatigue, pain, dyspnea (most common triad)

Lymphoma

  • Fatigue, pain, dyspnea

Leukemia

  • Fatigue, pain, loss of appetite (distinguishing feature)

MDS/MPN

  • Fatigue, dyspnea, depression or anxiety (distinguishing feature)

Important Context: Black/African American individuals present with more severe symptoms at diagnosis, including increased anemia, higher calcium levels, worse renal dysfunction, and more extramedullary disease 3. They also experience higher rates of cytokine release syndrome during CAR T-cell therapy 3.

Practical Diagnostic Approach

When encountering these atypical presentations:

  1. Maintain high clinical suspicion in patients with unexplained cutaneous, neurologic, ocular, rheumatologic, or hepatic findings
  2. Order complete blood count with differential as initial screening
  3. Pursue tissue diagnosis via biopsy of affected organs (skin, lymph node, bone marrow, liver) with flow cytometry and immunohistochemistry
  4. Avoid premature closure with rheumatologic or dermatologic diagnoses when clinical course is atypical or refractory to standard therapy
  5. Consider bone marrow biopsy when peripheral findings are suggestive but inconclusive

Critical Caveat: Diagnostic delays from misattribution to benign conditions significantly impact treatment outcomes and patient prognosis 5. The psychologic toll of delayed diagnosis on patients is substantial 5.

References

Guideline

acute myeloid leukemia, version 3.2023, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2023

Guideline

multiple myeloma, version 5.2026, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2026

Research

Hematologic focal hepatic lesions in the absence of liver cirrhosis: Consider lymphoma and myeloma.

Clinics and research in hepatology and gastroenterology, 2026

Research

Symptom burden and palliative care in patients with hematologic malignancies: a single-center experience.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.